Simone is a co-founder of Myopax, inventor of MyoPax proprietary technology, a clinical and scientific advisor and a board member. She is a professor of myology and heads both the Charité Outpatient Clinic for Muscle Disorders and the Muscle Research Unit at Charité and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association.


Simone has more than 30 years of experience in clinical care of patients with muscle diseases. She represents the sponsor (Charité) for the first clinical trial of the muscle stem cell therapeutic Satori-01. Simone has a vigorous scientific background in immunology and skeletal muscle. Her research group is doing pioneering work in the development of new technologies for muscle therapies including gene correction using CRISPR/Cas editing. Simone founded the first international graduate school in skeletal muscle, MyoGrad.

She studied medicine in Würzburg, Germany, and completed internships at Harvard and Johns Hopkins Medical School. Her focus settled on muscle after she completed a two-year clinical fellowship at the Mayo Clinic in Rochester, US, working with Dr. Andrew Engel, a world-leading expert in the field. Simone is a member of several international advisory boards for the development of muscular dystrophy therapies.

Verena is a co-founder and the CEO of MyoPax. She is a physician trained in myology and clinical pharmacology. Verena holds a Master of Business Administration, in which she focused on the Advanced Therapy Medicinal Product market.


Verena spent several years diagnosing and caring for patients with muscle diseases at the Charité Universitätsmedizin in Berlin and had the opportunity to learn from and work closely with Simone Spuler. She conducted several years of basic research on skeletal muscle at the Charité and the Max Delbrueck Center for Molecular Medicine. More recently, Verena has been dedicated to the preclinical and clinical development of the Satori muscle stem cell product and to securing its non-dilutive funding. 

Before coming to Berlin, she studied medicine at the Ruprecht-Karls-University in Heidelberg and the University of Rostock. She has worked in London, UK and Stellenbosch, South Africa. Verena grew up in several European countries.

Executive Team

Eric is the MyoPax principal stem cell scientist. He has many years of experience in studying the human muscle stem cell and in engineering myogenic cells from human induced pluripotent stem cells (hiPSCs).


Prior to joining MyoPax, he was a postdoctoral researcher at the Max Delbrück Center for Molecular Medicine and the Charité Universitätsmedizin Berlin alongside Simone Spuler and Sebastian Diecke. During his PhD, he was affiliated with MyoGrad, an international research training group for myology. His thesis centred on hiPSC generation and redifferentiation into induced myogenic cells. He is a member of the International Society for Stem Cell Research (ISSCR) and the German Stem Cell Network (GSCN). 

Eric studied biological sciences at the University of Konstanz (BSc), the Technical University of Darmstadt (MSc) and the Freie University Berlin (PhD). He has experience in the pharmaceutical and food industries.

Mark is a scientist and an engineer. He is our strategist for manufacture and compliance.


Prior to joining MyoPax, he was a senior advisor in the Muscle Research Unit at the Charité Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine.

Mark has more than 30 years of experience in academic, industrial and non-profit biomedical environments covering artificial organ engineering, medical device development/certification and development/manufacture/regulation of tissue transplants and advanced therapeutics. He is a member of the DIN/ISO expert technical committees for aseptic processing and for assurance of sterility.

Mark studied biological sciences at Glasgow University and has a PhD in Bioengineering from the University of Strathclyde.